Zhemal Khamidun
Hamidun News editorial desk led by Editor-in-Chief Zhemal Khamidun (CPO of AlpinaGPT). Daily curation across 50+ global AI labs, research feeds, and industry reports in 6 languages.
Linkerbot prepares for a Hong Kong IPO: rise of the Chinese robot-arm maker
Startup Linkerbot, which develops high-precision robotic arms for industry and logistics, is considering a listing on the Hong Kong stock exchange, insiders say.
Pentagon signs $500 million contract with Meta-backed Scale AI
The Pentagon has selected Meta-backed Scale AI to analyze data and support decision-making in the armed forces under a $500 million contract. *Meta is designated an…
Ukraine seizes a position with drones and robots for the first time — developer becomes a unicorn
Ukrainian troops in April seized an enemy position using only unmanned systems. The developer company was valued at $1 billion.
IBM to Receive $1 Billion from US for First Quantum Chip Factory
Swiss startup creates four-armed robot for space stations
Code Protection Without YAML: How GitLab Scales Scanning
The New York Times Union Demands Information on AI Usage
GitLab 19.0 introduces SBOM-based dependency scanning for vulnerability protection
GitLab released a new dependency scanning feature that not only searches for known vulnerabilities in packages, but shows which ones are actually used in the code…
To Pay or Not to Pay for Transcription: Comparing Paid and Free Services
A Wired author tested popular speech-to-text services and found out whether paid subscriptions make sense or if free alternatives are enough for most users.
Students Have Lost the Ability to Read Long Texts — Teachers Blame AI
Graduates Boo Speakers Praising AI at Commencement Ceremonies — Microsoft Calls for Dialogue
Francisco Partners raises record $18 billion despite M&A crisis
GM launches V2G: electric vehicles will power data centers
From Big Pharma to Nature: How a Merck Chemist Became a Natural Drug Designer
Tim Chernack spent two decades developing precision therapy at Big Pharma, but in 2018 chose a different path: bio-inspired design of molecules from nature.
David Sinclair to Test Anti-Aging Drugs in XPrize Competition
Harvard gerontologist David Sinclair plans to test the effectiveness of anti-aging drugs in the international innovation competition XPrize.